CTOs on the Move

Cortendo AB

www.cortendo.com

 
Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cortendo.com
  • 900 Northbrook Drive Suite 200
    Trevose, PA USA 19053
  • Phone: 610.254.9200

Executives

Name Title Contact Details

Similar Companies

Affinor Growers

Affinor Growers are excited to bring you fresh, non-GMO, delicious food grown in pristine environments without pesticides or chemicals. We are building facilities to grow dark, leafy green vegetables such as Spinach and Lettuce with near zero-water waste. We are an industry leader growing water-fed, nutrient rich strawberries. Affinor will grow in a safe, secure environment with focus on analytical results. Our scientists are always exploring new ways to produce high quality, premium medical marihuana strains and plants for medicinal purposes. Patients will appreciate the pain relieving quality and safety of our trusted products.

Innovate Biopharmaceuticals

Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.